CALCULATE YOUR SIP RETURNS

Bafna Pharmaceuticals Share Price Live

BAFNAPH

Small Cap | Pharmaceuticals

145.59

+2.85(2.00%)

Live Bafna Pharmaceuticals Share Price Chart

Bafna Pharmaceuticals Performance

Days Range

Previous Close₹142.74
Open₹0
Volume875
Day's Range₹143.42 - ₹145.59
52W Range₹69.00 - ₹202.06
Market Cap₹339.47 Cr

Bafna Pharmaceuticals Fundamentals

ROCE(TTM)0.00
P/E Ratio (TTM)0
P/B Ratio4.3
Industry P/E40.21
Debt to Equity2.88
ROE0.00
EPS (TTM)0
Dividend Yield0
Book Value21.61
Face Value10
ROCE(TTM)0.00
P/E Ratio (TTM)0
P/B Ratio4.3
Industry P/E40.21
Debt to Equity2.88
ROE0.00
EPS (TTM)0
Dividend Yield0
Book Value21.61
Face Value10

Bafna Pharmaceuticals Financials

Sep 2018Jun 2019Sep 2019
Net Sales8.846.8511.57
Expenses9.4110.7312.66
Profit before tax-1.22-3.71-0.55
Operating Profit-1.28-2.13-0.59
Net Profit-1.28-2.13-0.59
ESP in Rs-0.80-0.90-0.25

Bafna Pharmaceuticals Shareholding Pattern

Held bySep 2024Dec 2024Mar 2025Jun 2025Sep 2025
Promoters88.3%88.3%75%75%75%
Flls0%0%8.53%9.34%9.34%
Dlls0%0%0%0%0%
Public11.7%11.7%16.47%15.66%15.66%

About Bafna Pharmaceuticals

Bafna was started as a proprietary concern in 1981 by Mr. Bafna Mahaveer Chand in the name of Bafna Pharmaceutical and has been engaged in the business of manufacturing pharmaceutical formulations of Betalactum and Non Betalactum products. The first manufacturing unit was set up at Madhavaram (Chennai) during October 1984 for manufacture of tablets with an installed capacity of 420 lacs tablets p.a. Subsequently the capsule line was added during 1987 with a capacity of 300 lacs capsule p.a. and then liquid line with an installed capacity of 45000 lts p.a was added in 1990. During the year 1995, Bafna Pharmaceuticals Limited was incorporated and it acquired the entire business of the proprietary concern. During the year 2001, the company constructed a separate block at Madhavaram for manufacturing Betalactum products. During 2006, Bafna has set up a 100% EOU unit at Madhavaram for the production of tablets and capsule with a capacity of 6973.20 lacs and 2462.40 lacs. This facility has been set up as per revised Schedule M under the Drugs and Cosmetics Act, 1947. The unit has been WHO GMP certified and also ISO 9000 certified. The manufactured products in this factory catered to the markets of Srilanka, Ghana and Ukraine. Bafna was carrying on contract manufacturing for M/s Croslands Pvt. Ltd, a Mumbai based Pharmaceutical Company during the period 1994 to 2000. The company's first product was registered in Srilanka in 1995 and the company made its first export during the same year. Presently around 57 products of the company are registered in Srilanka. During the year 2000 Bafna registered 3 of its products in Lao and in the year 2006, 4 products were registered in Ukraine. During 2007, Bafna registered 1 product in Ghana. The products registered by the company cover all the therapeutic segments. In the year 2003, the Government of India granted the Export House status to the company. The company received the Best Supplier award from the Srilankan Government during 2005. After establishing itself in the non -regulated market, the company decided to enter into a more lucrative and regulated market of Europe. Towards this objective, the company started construction of a new state of art facility at Grantlayon village, near Red hills, Chennai for the manufacture of Non Betalactum products in solid oral dosage form during 2005. This unit is a 100% EOU unit. The factory was completed and inaugurated on October 2, 2006. This new plant has been set up with guidelines as laid down in European GMP. The machineries installed in the new facility of the company are Programmable Logic Controller and all the contact parts are made of stainless steel. This leads to consistent quality of products produced with no contamination. The Auto Coater machinery used in the unit is imported from Korea and Camera system for detection of unfilled product is imported from USA. The company has entered into an agreement with an UK based company Somex Pharma for sale of cholesterol lowering agent products to be manufactured by Bafna at this unit. A full-scale commercial production would be commenced in the new unit once approval of MHRA is received. Presently company is validating the equipments and process at this unit and taking validation batches for trail run.

Parent Organisation
Indian Private
Managing Director
Ravichandran Chitra
Founded
1995
NSE Symbol
BAFNAPH

Bafna Pharmaceuticals Share Price History

Bafna Pharmaceuticals Share Price History

ParticularsDetails
5-Year % change in Bafna Pharmaceuticals share price268.55%
5-Year Highest in Bafna Pharmaceuticals share price₹ 233.55
5-Year Lowest in Bafna Pharmaceuticals share price₹ 20.35
1-Year % change in Bafna Pharmaceuticals share price-24.7%
1-Year Highest in Bafna Pharmaceuticals share price₹ 99.6
1-Year Lowest in Bafna Pharmaceuticals share price₹ 69

Top Mutual Funds Invested in Bafna Pharmaceuticals Share

Top Mutual Funds Invested in Bafna Pharmaceuticals Share

FUND NAMEAUM(%)

Peer Comparison

Peer Comparison

StocksLTP (₹)Market Cap (cr)52 Week Low-High (₹)
Sun Pharmaceutical Industries Ltd1,794.1
-13.10 (-0.72%)
₹4,33,535.841,548.0 - 1,910.0View Stocks
Divis Laboratories Ltd6,419.0
-11.00 (-0.17%)
₹1,70,753.374,955.0 - 7,071.5View Stocks
Torrent Pharmaceuticals Ltd3,794.8
-4.20 (-0.11%)
₹1,28,644.102,886.45 - 3,882.2View Stocks
Cipla Ltd1,516.4
4.10 (0.27%)
₹1,22,143.091,335.0 - 1,673.0View Stocks
Dr Reddys Laboratories Ltd1,278.9
5.40 (0.42%)
₹1,06,244.271,020.0 - 1,405.9View Stocks
Lupin Ltd2,114.2
32.40 (1.56%)
₹95,030.141,795.2 - 2,402.9View Stocks

Bafna Pharmaceuticals Ltd FAQs

Bafna Pharmaceuticals Ltd (BAFNAPH) share price as of December 12, 2025, on NSE is Rs 145.59 (NSE) and Rs 145.59 (BSE) on BSE.
Yes, You can buy Bafna Pharmaceuticals Ltd (BAFNAPH) shares by opening a Demat account with Angel One.
Bafna Pharmaceuticals Ltd (BAFNAPH) share can be bought through the following modes:
1. Direct investment: You can buy Bafna Pharmaceuticals Ltd (BAFNAPH) shares by opening a Demat account with Angel One.
2. Indirect investment: The indirect method involves investing through ETFs and Mutual Funds that offer exposure to Bafna Pharmaceuticals Ltd (BAFNAPH) shares.
Open Free Demat Account!
Join our 3 Cr+ happy customers